Cooper Companies Inc

Cooper Companies Inc(COO)の株式分析

$57.400

+2.635 (+4.59%)終値時点

Loading chart…
高値
57.470
始値
55.490
出来高加重平均価格
56.78
出来高
2.89M
時価総額
17.45B
安値
55.460
売買代金
163.84M
EV/EBITDA(TTM)
9.81

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

www.coopercos.com

AI分析 of Cooper Companies Inc (COO)

中立

Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.

アナリスト評価(15)

上値余地 +57.37%
買い
10 買い
5 中立
0 売り
現在: 57.40
安値
73.00
平均
90.33
高値
100.00

Barclays

2026-10-06

目標株価

$60

Equal Weight

Mizuho

2026-09-11

目標株価

$75

アウトパフォーム

JPMorgan

2026-09-10

目標株価

$58

中立

Needham

2026-09-10

目標株価

$73

買い

Citi

2026-09-10

目標株価

$60

中立

バリュエーション指標

Cooper Companies Inc(COO)の現在の予想PERは11.34で、5年平均は22.86です。

予想PER

大幅な割安
5年平均 P/E
22.86
現在のP/E
11.34
割高
28.02
割安
17.71

予想EV/EBITDA

適正
5年平均 EV/EBITDA
19.30
現在のEV/EBITDA
9.81
割高
45.90
割安
-7.31

予想PSR

大幅な割安
5年平均 P/S
4.37
現在のP/S
2.35
割高
5.32
割安
3.43

Alphio AI による COO の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%COO

$100.88

シナリオ価格

基

基本

基本 · 50%COO

$92.29

シナリオ価格

弱

弱気

弱気 · 25%COO

$83.71

シナリオ価格

COO を保有するクジラ

G

Generation Investment Management LLP

+ を保有COO

+11.12%

3か月リターン

T

Trajan Wealth, L.L.C.

+ を保有COO

+6.51%

3か月リターン

S

Sustainable Growth Advisers, LP

+ を保有COO

+5.81%

3か月リターン

H

HBK Investments L.P.

+ を保有COO

+2.71%

3か月リターン

S

Staley Capital Advisers, Inc.

+ を保有COO

+2.60%

3か月リターン

H

Heartland Advisors, Inc.

+ を保有COO

+2.01%

3か月リターン

COO のよくある質問 — Alphio AI が回答

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める